31 August 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce the Company’s interim results for the six months to 30 June 2022, on 6 September 2022.
Jeremy Skillington, Chief Executive Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 6 September 2022 at 18:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Poolbeg Pharma here . Investors who already follow Poolbeg Pharma on the Investor Meet Company platform will automatically be invited. The presentation and recording will be available on the Company’s website after the event here .
– Ends –
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+44 (0) 207 183 1499
